Jade Biosciences (JBIO) Operating Leases (2021 - 2026)

Jade Biosciences' (JBIO) quarterly Operating Leases came in at $679000.0 in Q1 2026, down 6.22% on a QoQ basis from $724000.0 in Q4 2025.

Jade Biosciences (JBIO) Operating Leases (2021 - 2026) Analysis & Trends

Jade Biosciences (JBIO) has 6 years of Operating Leases data on file, last reported at $679000.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $679000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $679000.0 (changed N/A YoY) and the FY2025 annual result came in at $724000.0, changed N/A from the prior year.
Operating Leases fell to $679000.0 in Q1 2026, from $724000.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $1.2 million in Q2 2022 to a low of $81000.0 in Q3 2024.
A 5-year average of $562200.0 and a median of $591000.0 in 2023 frame the typical range for Operating Leases.
Annual changes were most pronounced in 2024 — Operating Leases slumped 77.37% — and 2025, when it jumped 764.2%.
Tracing JBIO's Operating Leases over 5 years: stood at $705000.0 in 2022, then tumbled by 63.83% to $255000.0 in 2023, then plunged by 68.24% to $81000.0 in 2024, then soared by 793.83% to $724000.0 in 2025, then declined by 6.22% to $679000.0 in 2026.
The last three Operating Leases figures came in at $679000.0 (Q1 2026), $724000.0 (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Jade Biosciences	1.57 Bn	1.11 Bn	-

Download Data